Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer
Q Wang, X Ma, H Wu, C Zhao, J Chen, R Li… - …, 2022 - Taylor & Francis
The improved survival rate of ovarian cancer (OC) is related to the action of infiltrating
cytotoxic T lymphocytes (CTLs). Recently, oncolytic adenoviruses (OAds) have emerged as …
cytotoxic T lymphocytes (CTLs). Recently, oncolytic adenoviruses (OAds) have emerged as …
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
S Basnet, JM Santos, DCA Quixabeira… - Molecular Therapy …, 2023 - cell.com
Immunotherapy with bispecific T cell engagers has shown efficacy in patients with
hematologic malignancies and uveal melanoma. Antitumor effects of bispecific T cell …
hematologic malignancies and uveal melanoma. Antitumor effects of bispecific T cell …
High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment
J Ma, C Zhang, G Shi, D Yue, Y Shu, S Hu, Z Qi… - Molecular Therapy, 2022 - cell.com
Preclinical and clinical studies have validated the antitumor effects of several oncolytic
viruses (OVs). However, the efficacy of OVs is limited when they are administered as …
viruses (OVs). However, the efficacy of OVs is limited when they are administered as …
M11: a tropism-modified oncolytic adenovirus arming with a tumor-homing peptide for advanced ovarian cancer therapies
F Li, Y Yuan, Y Dai, T Cheng, H Cao, D Yan… - Human Gene …, 2022 - liebertpub.com
Oncolytic adenoviruses (OAds) have shown great promise in cancer therapy, but their
efficacy has been greatly limited by poor tumor selectivity and highly off-target liver …
efficacy has been greatly limited by poor tumor selectivity and highly off-target liver …
[HTML][HTML] Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
JM Santos, C Heiniö, V Cervera-Carrascon… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Ovarian cancers often contain significant numbers of tumor-infiltrating
lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT) …
lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT) …
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model
L Kuryk, ASW Møller, M Garofalo… - Journal of Medical …, 2018 - Wiley Online Library
Oncolytic adenoviral immunotherapy activates the innate immune system with subsequent
induction of adaptive tumor‐specific immune responses to fight cancer. Hence, oncolytic …
induction of adaptive tumor‐specific immune responses to fight cancer. Hence, oncolytic …
Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy
CA Fajardo, S Guedan, LA Rojas, R Moreno… - Cancer research, 2017 - AACR
Antiviral immune responses present a major hurdle to the efficacious use of oncolytic
adenoviruses as cancer treatments. Despite the existence of a highly immunosuppressive …
adenoviruses as cancer treatments. Despite the existence of a highly immunosuppressive …
[HTML][HTML] Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
Y Su, J Li, W Ji, G Wang, L Fang, Q Zhang… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Oncolytic virotherapy has become an important branch of cancer
immunotherapy. This study investigated the efficacy of an oncolytic adenovirus (OAV) …
immunotherapy. This study investigated the efficacy of an oncolytic adenovirus (OAV) …
Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse …
H Zhang, W Xie, Y Zhang, X Dong, C Liu, J Yi… - Cancer Gene …, 2022 - nature.com
Effective therapeutic strategies for triple-negative breast cancer (TNBC) are still lacking.
Clinical data suggest that a large number of TNBC patients cannot benefit from single …
Clinical data suggest that a large number of TNBC patients cannot benefit from single …
[HTML][HTML] MUC16 affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells
Y Zhai, Q Lu, T Lou, G Cao, S Wang… - Annals of Translational …, 2020 - ncbi.nlm.nih.gov
Background Ovarian cancer is the 5 th most common lethal gynecological malignancy with a
5-year survival rate of about 47% and a localized stage diagnosis of 15%, leading to about …
5-year survival rate of about 47% and a localized stage diagnosis of 15%, leading to about …